XOMA Corp XOMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XOMA is a good fit for your portfolio.
News
-
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL)
-
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA
-
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol
Trading Information
- Previous Close Price
- $24.25
- Day Range
- $24.24–25.06
- 52-Week Range
- $13.48–27.00
- Bid/Ask
- $15.76 / $39.01
- Market Cap
- $286.11 Mil
- Volume/Avg
- 14,874 / 19,680
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 58.78
- Dividend Yield (Trailing)
- 2.19%
- Dividend Yield (Forward)
- 8.77%
- Total Yield
- 2.19%
Company Profile
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.xoma.com
Comparables
Valuation
|
Metric
|
XOMA
|
CGEM
|
PTGX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.16 | 1.71 | 4.32 |
Price/Sales | 58.78 | — | 23.86 |
Price/Cash Flow | — | — | — |
Price/Earnings
XOMA
CGEM
PTGX
Financial Strength
|
Metric
|
XOMA
|
CGEM
|
PTGX
|
|---|---|---|---|
Quick Ratio | 8.65 | 16.60 | 16.54 |
Current Ratio | 8.68 | 17.07 | 16.71 |
Interest Coverage | −70.76 | — | — |
Quick Ratio
XOMA
CGEM
PTGX
Profitability
|
Metric
|
XOMA
|
CGEM
|
PTGX
|
|---|---|---|---|
Return on Assets (Normalized) | 2.74% | −24.60% | −16.60% |
Return on Equity (Normalized) | 3.83% | −25.95% | −18.20% |
Return on Invested Capital (Normalized) | 3.54% | −29.67% | −23.45% |
Return on Assets
XOMA
CGEM
PTGX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qkssqfjsz | Kwkd | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lrrcprpx | Gttmgjz | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Tvwyxftzn | Xtxyv | $98.1 Bil | |
MRNA
| Moderna Inc | Wcrfvdy | Rms | $39.1 Bil | |
ARGX
| argenx SE ADR | Yrblrrm | Qpdq | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Kjjtjfdt | Frhzz | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xmqqqcr | Ybrndsc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Npptctnlm | Pgnwtb | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ggzzmdkxk | Wjzylh | $12.5 Bil | |
INCY
| Incyte Corp | Xcwxqkpt | Ynhrmg | $11.9 Bil |